Human single chain-transbodies that bound to domain-I of non-structural protein 5A (NS5A) of hepatitis C virus

Kittirat Glab-ampani1,2, Monrat Chulanetra2, Aijaz Ahmad Malik2, Thanate Juntadech2, Jeeraphong Thanongsaksriku1, Potjanee Srimanote3, Kanyarat Thueng-in4, Nitat Sookrung2, Pongsri Tongtawe3 & Wanpen Chaicumpa2,3

A safe and broadly effective direct acting anti-hepatitis C virus (HCV) agent that can withstand the viral mutation is needed. In this study, human single chain antibody variable fragments (HuscFvs) to conserved non-structural protein-5A (NS5A) of HCV were produced by phage display technology. Recombinant NS5A was used as bait for fishing-out the protein bound-phages from the HuscFv-phage display library. NS5A-bound HuscFvs produced by five phage transfected E. coli clones were linked molecularly to nonaarginine (R9) for making them cell penetrable (become transbodies). The human monoclonal transbodies inhibited HCV replication in the HCVcc infected human hepatic cells and also rescued the cellular antiviral immune response from the viral suppression. Computerized simulation verified by immunoassays indicated that the transbodies used several residues in their multiple complementarity determining regions (CDRs) to form contact interface with many residues of the NS5A domain-I which is important for HCV replication complex formation and RNA binding as well as for interacting with several host proteins for viral immune evasion and regulation of cellular physiology. The human monoclonal transbodies have high potential for testing further as a new ramification of direct acting anti-HCV agent, either alone or in combination with their cognates that target other HCV proteins.

Hepatitis C virus (HCV) is an enveloped plus-sense, single stranded-RNA virus of the genus Hepacivirus, family Flaviviridae. The virus infects about 3% of the global population leading to more than 700,000 HCV-related deaths annually1. Majority of the infection (~80%) turns to life-long chronic hepatitis which over decades can transform to liver fibrosis, decompensated cirrhosis, and/or hepatocellular carcinoma2,3. Currently, there is no effective vaccine against the infection. Before 2011, weekly injected pegylated alpha-interferon (IFNα) together with daily intake of ribavirin (RBV; 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide) which is a purine analog for 24–48 weeks, often called standard-of-care (SOC) or dual therapy, was a treatment mainstay for HCV infected patients4. It is thought that the IFN helps to restore the host innate immunity that has been suppressed by the HCV proteins (NS3/4A protease, NS4B, NS5A and core)5 while the RBV causes aberration of the viral replication. Response rates to SOC, defined as sustained virologic response (SVR) or a lack of detectable HCV 12–24 weeks following treatment completion vary greatly depending on the infecting HCV genotypes. Strains of genotypes 1 and 4 are relatively refractory to the regime6,7. The SOC protocol is prolonged, highly stringent and also conferred intolerable adverse effects which led to compliance preclusion by a significant portion of the recipients6. After 2011, treatment strategy for HCV infection has turned to the use of recently developed direct acting anti-HCV agents (DAAs) which are small molecular inhibitors of the viral enzymes or proteins8.

1Graduate Program in Immunology, Department of Immunology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand. 2Center of Research Excellence on Therapeutic Proteins and Antibody Engineering, Department of Parasitology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand. 3Graduate Program in Biomedical Science, Faculty of Allied Health Sciences, Thammasat University, Pathumthani province, 12120, Thailand. 4School of Pathology, Institute of Medicine, Suranaree University of Technology, Nakhon-ratchasima province, Thailand. Correspondence and requests for materials should be addressed to W.C. (email: wanpen.cha@mahidol.ac.th)
The new DAAs together with SOC (triple therapy) or different combinations among the inhibitors themselves conferred improved SVR rates9–13. Nevertheless, the novel treatment protocols are too complicated as they must be adjusted according to individual patients' clinical manifestations, circumstances, and treatment histories as well as the infecting HCV genotypes14. They are contraindicated to certain groups of patients15 as well as causing additional adverse effects16. The new DAA drugs/ regimens (particularly when the new inhibitors are administered singly) caused emergence of drug and cross-drug resistant HCV mutants9,12,13. Thus, there is still a need of a novel anti-HCV remedy that is safe (preferably interferon-free) and broadly effective against different HCV strains/genotypes.

HCV replication takes place at the virally induced-cellular organelle called replication complex (RC) which is a membrane web on endoplasmic reticulum (ER) of hepatocyte where many HCV and host proteins adjoin14. In the infected cell, positive-sense-HCV genome (∼9600 nucleotides) is translated directly into a polyprotein which is cleaved co- and post-translationally by host and viral proteases into four structural (core, E1, E2, and p7) and 6 non-structural (NS) proteins (NS2, NS3, NS4A, NS4B, NS5A, and NS5B) of diverse activities15. The NS5A (447 residues) is a hydrophilic multifunctional non-enzymatic protein that pivotal involved in the HCV replication and viral morphogenesis as well as regulation of several cellular signaling pathways16–19. The protein modulates hepatic cell physiology for the viral fitness and replication, antagonizes cellular apoptosis and initiates tumorigenesis leading consequently to hepatocellular carcinoma16,20–23. NS5A binds to HCV RNA for replication24. The protein exists in two phosphorylated forms, designated p56 and p58 according to their relative molecular masses in electrophoresis (56 and 38 kDa, respectively)25. The p56 is basically phosphorylated possibly by host casein kinase II at the center and near the C-terminus26. The p58 is hyperphosphorylated at the center serine-rich region by cellular kinases, one of which is a casein kinase I-α (CKI-α) with a cooperative mechanism that is believed to involve other HCV NS proteins on the same polyprotein27–29. NS5A N-terminal (residues 5–25) acquires an amphipathic helix (AH) configuration which anchored the protein to the cell membrane30,31. The remaining portion of NS5A in the cytoplasm contains three distinct domains: I (residues 28–213), II (residues 250–342), and III (residues 356–447) which are connected by low complexity sequences (LCS-I and LCS-II)17,19,32,33. Domain-I contains a cysteine-rich zinc coordination motif and is essential for HCV replication32,33. Crystal structure of the domain-I homodimer revealed a large basic groove at the N-terminalcontact interface of the two molecules; this groove is believed to involve RNA binding during the viral replication33,34. Intracellular NS5A regulates cellular physiology and host responses and cooperates with other HCV proteins including NS4B, NS5B and core and also several host proteins for viral replication and assembly35. Because the NS5A has multiple pivotal roles in the HCV infectious cycle and pathogenesis, the protein is an attractive target of the newly developed small chemical inhibitors17,36.

Results and Discussion
Recombinant full-length NS5A and NS5A domains I (D1), II (D2), and III (D3). DNA constructs for production of the recombinant 6 × His-tagged-NS5A (rNS5A) and the GST-tagged D1, D2, and D3 of NS5A in transformed E. coli clones carrying the recombinant plasmids with the respective NS5A gene inserts are illustrated in Fig. 1A. The 6 × His tag was fused with the recombinant NS5A for facilitating subsequent protein purification by using HisTrap FF column (GE Healthcare, UK) and for tracing the protein by using anti-6 × His tag antibody. The relative molecular mass of the rNS5A in the Western blot analysis was about 70 kDa (Fig. 1B). The higher molecular weight of the recombinant protein than the native counterpart (56/58 kDa) should be due to the contiguous 6 × His and the additional residues derived from the plasmid flanking regions. The recombinant D1, D2, and D3 of NS5A were produced as GST-tagged proteins and purified by using GSTrap FF affinity column (GE Healthcare) (Fig. 1B). These proteins were used subsequently for mapping the regions of NS5A molecule that bound to the HuscFvs. All recombinant proteins were verified by LC-MS/MS as the HCV NS5A proteins (data not shown).

HuscFvs that bound to recombinant NS5A. Full-length rNS5A was used as antigen in the phage biopanning for selecting HuscFv-displayed phage clones from a previously constructed HuscFv-phage display library37. The rNS5A-bound phages were used to transfect HB2151 E. coli and the bacteria were spread on LB-A selective agar plates. From 300 E. coli colonies that grew on the plates, 122 colonies were positive for HuscFv-coding sequences (huscfs) as detected by direct colony PCR35. Examples of the huscfs amplicons (∼1,000 bp) are shown in upper block of Fig. 2A. Among the 122 huscfs-positive HB2151 E. coli clones, lysates of 51 clones contained soluble E-tagged-HuscFv proteins after growing the bacteria under IPTG induction condition. Western blot patterns of the HuscFv representatives probed with rabbit anti-E-tag antibody are shown in lower block of Fig. 2A. Among the 51 clones, HuscFvs in lysates of 5 transformed E. coli clones (5, 9, 16, 19, and 99) gave significant indirect ELISA signals (OD405 nm) to the NS5A above the BSA control (Fig. 2B). Binding of the HuscFvs of these E. coli clones to rNS5A was verified by Western blot analysis (Fig. 2C). NS5A-bound HuscFvs of these E. coli clones were used further.

Human single chain antibody fragments (HuscFvs) that bound to NS5A were produced by using phage display fragmenting into living cells37. Most CPPs carry positive charge which facilitates electrostatic interactions with negatively charged cell-surface constituents. Typically, they are not exceeding 30 residues in length. Nonaarginine (R9) is one of such CPPs that has been shown to effectively deliver the cargo into cytoplasm38,39. In this study, human single chain antibody fragments (HuscFvs) that bound to NS5A were produced by using phage display technology. The HuscFvs were linked molecularly to the R940 in order to make them cell penetrable or become “transbodies”. The R9-HuscFv fusion proteins readily entered HCV infected human hepatic cells, inhibited the viral replication and restored the host innate immunity. Thus, they have potential for further development into another ramification of therapeutic agents against the HCV infection.
Cell penetrable monoclonal HuscFvs (transbodies). In order to interfere with the intracellular NS5A activity of the replicating HCV, the HuscFvs must be able to enter the host cells and interact with the intracellular target. Usually, mammalian plasma membrane is formidable for antibody molecules and conventional antibodies can function only extracellularly. To produce the cell penetrating HuscFvs, gene sequences coding for HuscFvs of the E. coli clones 5, 9, 16, 19, and 99 were linked to DNA sequence coding for a cell penetrating peptide (CPP), i.e., nonaarginine (R9), by means of the previously described ligase independent cloning (LIC) method. Purified R9-HuscFvs (∼30–36 kDa) of all E. coli clones after SDS-PAGE and Coomassie Brilliant Blue G-250 (CBB) staining are shown in Fig. 3. Ability of the R9-HuscFvs to enter the HCV infected human hepatic (Huh7) cells and bound to the intracellular native NS5A target was determined by laser sectional confocal microscopic assay. Figure 4 shows intracellular R9-HuscFv99 (as a representative) in red-fluorescence, intracellularly produced NS5A in green-fluorescence and nuclei in blue. Co-localization of the R9-HuscFv99 and the native NS5A which appeared in yellow/orange after merging at different levels of the cell sections are seen.

Immunoprecipitation to demonstrate binding of the R9-HuscFvs to native NS5A. HCV infected cells that had been exposed to R9-HuscFvs for 3 days were lysed and the NS5A in their lysates were fish-out using Protein-G beads coated with mouse anti-NS5A antibody. The preparations were subjected to Western blot analysis and the results are shown in Fig. 5. Native NS5A in the preparation are seen as protein bands at ∼55 kDa after the SDS-PAGE-separated preparations were probed with mouse anti-NS5A (upper block of Fig. 5). The same preparations also contained the respective R9-HuscFvs (∼30–36 kDa) as detected by rabbit anti-E-tag (lower block of Fig. 5). The preparation derived from lysate of HCV infected cells without R9-HuscFv treatment revealed only the NS5A. The results indicate that the R9-HuscFvs bound to native NS5A.

Human monoclonal transbodies-mediated HCV replication inhibition. Animal model of HCV infection is lacking. However in 2005, the HCV replicon system for HCV replication and production of the infectious viral particles in cell culture (HCVcc) was invented. The system has made the investigations on several attributions of the HCV and the HCV infection possible including the viral RNA replication, virus-host interactions, pathogenesis as well as for testing efficacy of innovative HCV inhibitors. HCV replicon was constructed by cloning the genome of genotype 2a HCV from a Japanese patient with fulminant hepatitis (JFH) into a plasmid. HCV RNA can be generated from the recombinant plasmid, designated pJFH-1, by digesting the plasmid with an endonuclease. The linearized plasmid is transcribed in vitro to generate cRNA and the cRNA is introduced into cultured human hepatic cells. The HCV replicates in the cells and infectious HCV particles (HCVcc) can be produced. In this study, ability of NS5A-bound R9-HuscFvs in inhibiting the HCV replication in the HCV infected Huh7 cells was investigated. The HCV infected cells were incubated with R9-HuscFv5, R9-HuscFv9, R9-HuscFv16, R9-HuscFv19, and R9-HuscFv99. Positive inhibitor controls were infected cells incubated with pegylated-IFNα + RBV (SOC) and telaprevir (a chemical inhibitor of HCV protease) and negative inhibitor was infected cells in culture medium alone. After 5 days, amounts of HCV 5′-UTR in the culture supernatants and cells of all treatment groups were determined by quantitative reverse transcription PCR (qRT-PCR).
of HCV 5′-UTR (copy numbers/ml) recovered from the culture supernatants and the respective HCV infected cells are shown in Fig. 6A and B, respectively. HCV infected cells in medium alone yielded the most HCV RNA copies in both culture supernatants and inside the cells. The HCV RNAs in culture supernatants and infected cells treated with the R9-HuscFvs and positive inhibitor controls were significantly less than the infected cells treated with pegylated-IFNα + RBV and R9-HuscFv19 (p < 0.05). The transbodies of the other E. coli clones were equally effective (p > 0.05). Overall results indicate that the NS5A-bound R9-HuscFvs caused inhibition of the HCV replication.

Infectious HCV foci formed inside the HCV infected cells of all treatments were determined by using mouse PAb to HCV core protein to probe the viral foci39. Results of the HCV foci enumeration (Fig. 6C) conformed to the 5′-UTR data. The infected cells in the medium alone produced many more HCV foci than in the infected cells treated with the R9-HuscFvs and positive inhibitors (p < 0.001). The number of HCV foci in the infected cells treated with the R9-HuscFv99 was not different from the telaprevir treated cells (p > 0.05) and both were the most effective inhibitors. HuscFvs produced by the five phage transformed-E. coli clones gave significant ELISA signals above the controls (dotted line). Panel C shows Western blot results for verification of binding of the HuscFvs to NS5A. The SDS-PAGE-separated NS5A blotted strips were incubated individually with HuscFv5, HuscFv9, HuscFv16, HuscFv19, and HuscFv99; the antigen-antibody reactive bands were revealed by using alkaline phosphatase (AP) conjugated-rabbit anti-E-tag and AP substrate (BCIP/NBT). M is molecular weight marker; NC is negative control which the SDS-PAGE-separated-NS5A blotted strip was incubated with PBS instead of HuscFv; PC is positive control which the SDS-PAGE-separated NS5A blotted strip was probed with mouse anti-6× His antibody, AP-anti-mouse isotype conjugate and BCIP/NBT substrate, respectively.

Figure 2. Production of NS5A-bound HuscFvs. Panel A (upper block) shows representative amplicons of HuScFv-coding genes (huscfvs) amplified from phage transformed-HB2151 E. coli colonies. The molecular mass of the huscfv was ~1,000 bp. Lower block shows HuscFvs produced by representative huscfv-positive E. coli clones (lanes 2, 5, 7, 9, and 10). Protein doublets are immature HuscFvs with signal peptides (upper bands) and mature HuscFvs without signal peptides (lower bands). Faint bands are degraded products of the principal proteins. Panel B shows results of indirect ELISA (OD405nm) for testing binding of the HuscFvs in lysates of the E. coli clones treated with the HuscFvs by using BSA as control antigen, lysate of original HB2151 E. coli as background antigen-binding control and rNS5A probed with mouse anti-6× His tag as positive control. HuscFvs produced by the five phage transformed-E. coli clones gave significant ELISA signals above the controls (dotted line). Panel C shows Western blot results for verification of binding of the HuscFvs to NS5A. The SDS-PAGE-separated NS5A blotted strips were incubated individually with HuscFv5, HuscFv9, HuscFv16, HuscFv19, and HuscFv99; the antigen-antibody reactive bands were revealed by using alkaline phosphatase (AP) conjugated-rabbit anti-E-tag and AP substrate (BCIP/NBT). M is molecular weight marker; NC is negative control which the SDS-PAGE-separated-NS5A blotted strip was incubated with PBS instead of HuscFv; PC is positive control which the SDS-PAGE-separated NS5A blotted strip was probed with mouse anti-6× His antibody, AP-anti-mouse isotype conjugate and BCIP/NBT substrate, respectively.
effective inhibitors for HCV focal formation. Effectiveness of telaprevir and R9-HuscFv99 was more than the pegylated-IFNα + RBV, R9-HuscFv5, R9-HuscFv9, R9-HuscFv16, and R9-HuscFv19, and R9-HuscFv99 stained with Coomassie Brilliant Blue G-250 (CBB) dye. Panel B illustrates patterns of the purified R9-HuscFvs in the Western blot analysis. Panel C shows indirect ELISA results to demonstrate that the R9-HuscFv fusion proteins still retained the NS5A-binding activity of the original HuscFvs.

Expression of the innate immune response genes in the HCV infected cells. Expressions of innate immune response genes including IRF3 (coding for type-1 interferon transcription factor), IFNB1 (type I interferon gene) and IL-28B (type III interferon gene) in the HCV infected hepatic cells and the hepatic cells stimulated with poly(I:C) at different times (1, 3, 6, 12, 24, 72 and 120 h) were determined by qRT-PCR in comparison to the uninfected cells. The RNA (300 ng) extracted from the infected/poly(I:C) treated cells was used as template for the qRT-PCR. GAPDH RNA was used for normalization. The results showed that cells stimulated
Figure 4. Cellular internalization and intracellular target binding activity of the R9-HuscFvs. Huh7 cells were incubated with R9−HuscFv99 (as representative). After incubation, the cells were fixed, permeated, and stained with rabbit anti-E tag followed by goat anti-rabbit immunoglobulin-AlexaFluor®−594 and donkey anti-mouse immunoglobulin-AlexaFluor®−488 and counterstained with DAPI for locating nuclei. The preparation was subjected to laser sectional confocal microscopy at 0.96 μm per section, i.e., 2.96, 3.92 and 4.88 μm from top to bottom. Intracellular NS5A appears in green; R9-HuscFv99 in red and nuclei in blue. The farthest right column demonstrates merge of all blocks of the same horizontal row.

Figure 5. Binding of the R9-HuscFvs to native NS5A as determined by immunoprecipitation test. Lysates of HCV infected Huh7 cells treated with R9-HuscFvs were mixed with protein G resin coated with mouse anti-NS5A antibody and subjected to Western blot analysis. The preparations from lysates of HCV infected cells treated with R9-HuscFv5, R9-HuscFv9, R9-HuscFv16, R9-HuscFv19 and R9-HuscFv99 after SDS-PAGE were found to contain both NS5A (detected by mouse anti-NS5A) and R9-HuscFvs (detected by anti-E tag). The preparation from HCV infected cells without R9-HuscFv treatment revealed only the NS5A. The results indicate that thr R9-HuscFvs bound to native NS5A.
with poly(I:C) started to have up-regulation of IRF3, IFNB1 and IL-28B at 1, 3 and 1 h, respectively, and the magnitudes of the responses increased at the later time points (Fig. 7A–C, respectively). On contrary, cells infected with HCV had down-regulation of the IRF3 and IFNB1 since the first hour of infection (Fig. 7A and B) while HCV-mediated suppression of the IL-28B was observed at 72 and 120 h post-infection (Fig. 7C). Suppression of the innate gene responses by the HCV was pronounced at day 5 post-infection. The data indicate that HCV could inhibit the host innate immune response gene expressions, most probably by using the early produced NS3/4A protease that has been known to cleave TRIF and Cardif/MAVS, binds to TBK1, and inhibits activation of innate interferon signaling pathways44–46.

**Response of HCV infected cells to treatment with the R9-HuscFvs.** RNAs were isolated from the HCV infected cells after the cells had been exposed for 5 days to the R9-HuscFv5, R9-HuscFv9, R9-HuscFv16, R9-HuscFv19, and R9-HuscFv99 in comparison with controls. Panel B shows comparative amounts of HCV 5′ UTR RNA in the infected cells after treatments. Panel C shows numbers of HCV foci in the HCV infected cells after being exposed to the R9-HuscFvs in comparison to the controls. Panel D depicts appearance of HCV foci in infected cells after treatments with various HCV inhibitors and controls. a-h, HCV foci in infected Huh7 cells treated with R9-HuscFv5, R9-HuscFv9, R9-HuscFv16, R9-HuscFv19, R9-HuscFv99, telaprevir, pegylated-IFNα-2a + RBV and medium alone, respectively; i, normal Huh7 cells.

**Figure 6.** Transbodies-mediated HCV replication inhibition. Panel A shows amounts of HCV 5′-UTR RNA in culture fluids of HCV infected cells after treating with the R9-HuscFv5, R9-HuscFv9, R9-HuscFv16, R9-HuscFv19, and R9-HuscFv99 in comparison with controls. Panel B shows comparative amounts of HCV 5′-UTR RNA in the infected cells after treatments. Panel C shows numbers of HCV foci in the HCV infected cells after being exposed to the R9-HuscFvs in comparison to the controls. Panel D depicts appearance of HCV foci in infected cells after treatments with various HCV inhibitors and controls. a-h, HCV foci in infected Huh7 cells treated with R9-HuscFv5, R9-HuscFv9, R9-HuscFv16, R9-HuscFv19, R9-HuscFv99, telaprevir, pegylated-IFNα-2a + RBV and medium alone, respectively; i, normal Huh7 cells.
to normal cells are shown in Fig. 8A–C, respectively. The R9-HuscFvs and the positive HCV replication inhibition controls (pegylated-IFNα + RBV and telaprevir) effectively restored the host gene expressions while apparent immune suppression was retained in the HCV infected cells kept in the medium alone ($p < 0.0001$). The data indicate that the R9-HuscFVs not only inhibited the viral replication, but also restored the host innate immune response. The transbodies should be relatively safe if used in treatment of HCV infection in humans (no anti-isotype/anti-R9 response in the treated human subjects). Usually, an antibody molecule uses several residues in their multiple CDR loops to cooperate in target binding. Such multiple site-binding should render difficulty for the HCV to mutate and create the transbody-escape, functional NS5A mutant. This is in contrast to the HCV small chemical inhibitors, such as telaprevir (HCV protease inhibitor) and sofosbuvir (NS5B polymerase inhibitor) which drug escape HCV mutants emerged rapidly by a single amino acid mutation of the target proteins47–50.

Figure 7. Kinetics of innate gene expression in HCV infected cells. Fold change in expressions of innate immune response genes including $\text{IRF}3$ (A), $\text{IFNB1}$ (B) and $\text{IL-28B}$ (C) in HCV infected Huh7 cells at different times after infection were determined by qRT-PCR using cells stimulated with poly(I:C) as positive control in comparison to the normal cells. Suppression of $\text{IRF}3$ and $\text{IFNB1}$ in the HCV infected cells were observed as early as 1 h post infection while the HCV-mediated $\text{IL-28B}$ suppression was detected at 72 h post infection. The HCV-mediated innate gene down-regulations were pronounced at 120 h post infection. The poly(I:C) started to up-regulate $\text{IRF}3$, $\text{IFNB1}$ and $\text{IL-28B}$ at 1, 3 and 1 h post stimulation, respectively; the gene up-regulations by poly(I:C) were observed until the end of the experiments.
Computerized simulation for determining regions and residues of the NS5A that were bound by the HuscFvs. Computerized simulation was performed to determine the presumptive NS5A regions and residues that formed contact interface with the effective HuscFvs in order to gain some insight into the mechanisms of the HuscFv-mediated HCV replication inhibition. From the homology modeling and intermolecular docking, the complexes formed between the modeled HCV NS5A and HuscFv5, HuscFv9, HuscFv16, HuscFv19, and HuscFv99 that revealed the largest interactive clusters with the lowest local energy scores were selected. According to the docking outputs, all HuscFvs were predicted to form contact interface mainly with domain-I of the NS5A (Table 1) and Fig. 9. It is known that N-terminal residues 5–25 of NS5A form amphipathic helix (AH) which anchors the protein to the web membrane for the RC formation\(^{31,32}\). This region also coordinates a zinc atom to the NS5A molecule\(^{33}\). Mutation disruption of either one of these two N-terminal activities inhibits HCV replication (hence lethal mutations)\(^{33}\). The HuscFv5 was predicted to interact with a conformational epitope formed by two NS5A N-terminal regions [residues D18 and L23 of AH and K26, L27, F36, I74, K78 and M81 of domain-I] and S229 and S232 of LCS-I] that are spatially juxtaposed upon the protein folding (Fig. 9A). Binding of the HuscFv5 to the AH and domain-I should interfere with both the NS5A localization at the web and the zinc ion coordination and should lead to impairment of HCV replication. Besides, the NS5A molecule is known

Figure 8. Fold change of mRNA expressions of the innate immune response genes in HCV infected cells after treating with the NS5A-bound-transbodies and controls (pegylated-IFNα-2a + RBV, telaprevir and medium alone) in comparison to normal (non-infected) cells. Panels A–C show fold change of expressions of IRF3, IFN-β and IL-28, respectively, after exposure to the transbodies and controls. The NS5A-bound-R9-HuscFvs and positive inhibitor controls restored the expressions of the innate genes that had been suppressed by the replicating HCV. All studied genes in the HCV infected cells cultured in medium alone were down-regulated by the infection.
| HCV NS5A protein | HuscFv5 |
|------------------|--------|
| Residues | Domain | Residue(s) | Domain | Interactive bond |
| D18 | AH of domain I | R104 | VH-CDR3 | Salt bridge |
| L23 | AH of domain I | K54 | VH-CDR2 | H-bond |
| K26 | Domain I | D33 | VH-CDR1 | Salt bridge |
| L27 | Domain I | S57 | VH-CDR2 | H-bond |
| F36 | Domain I | Y230 | VL-CDR3 | π-π interaction |
| I74 | Domain I | F105 | VH-CDR3 | H-bond |
| K78 | Domain I | S229 | VL-CDR3 | H-bond |
| M81 | Domain I | Y230 | VL-CDR3 | H-bond |
| S229 | LCS-I | S204 | VL-CDR3 | H-bond |
| S232 | LCS-I | S204/S190 | VL-CDR3 | H-bond |

| HCV NS5A protein | HuscFv9 |
|------------------|--------|
| Residues | Domain | Residue(s) | Domain | Interactive bond |
| I37 | Domain I | R189 | VL-CDR3 | H-bond |
| T108 | Domain I | S165 | VL-CDR1 | H-bond |
| F120 | Domain I | Y167 | VL-CDR1 | H-bond |
| D136 | Domain I | N54 | VH-CDR2 | Salt bridge |
| F165 | Domain I | T102 | VH-CDR3 | H-bond |
| K166 | Domain I | D31 | VH-CDR1 | Salt bridge |
| I74 | Domain I | Y33 | VH-CDR2 | π-π interaction |
| R170 | Domain I | Y167 | VL-CDR1 | H-bond |
| D171 | Domain I | N59 | VH-CDR1 | H-bond |
| E172 | Domain I | R65 | VH-CDR3 | Salt bridge |

| HCV NS5A protein | HuscFv16 |
|------------------|---------|
| Residues | Domain | Residue(s) | Domain | Interactive bond |
| K107 | Domain I | S54 | VH-CDR2 | H-bond |
| H124 | Domain I | T57 | VH-CDR2 | H-bond |
| Y127 | Domain I | K224 | VL-CDR3 | Salt bridge |
| Y129 | Domain I | Y59 | VH-CDR2 | π-π interaction |
| E191 | Domain I | N225 | VL-CDR3 | H-bond |
| R220 | Domain I | S30 | VH-CDR1 | H-bond |
| E226 | Domain I | S30 | VH-CDR1 | H-bond |
| D251 | Domain II | K224 | VL-CDR3 | Salt bridge |

| HCV NS5A protein | HuscFv19 |
|------------------|---------|
| Residues | Domain | Residue(s) | Domain | Interactive bond |
| H124 | Domain I | N31 | VH-CDR1 | H-bond |
| G125 | Domain I | R100 | VH-CDR3 | H-bond |
| Y127 | Domain I | Y106 | VH-CDR3 | H-bond |
| Y129 | Domain I | R98 | VH-CDR3 | H-bond |
| S186 | Domain I | R59 | VH-CDR3 | H-bond |
| E191 | Domain I | N102 | VH-CDR3 | H-bond |
| N248 | LCS-I | G26 | VH-CDR1 | H-bond |
| T249 | LCS-I | R98 | VH-CDR3 | H-bond |
| D251 | Domain II | R100/N105 | VH-CDR3 | Salt bridge |

| HCV NS5A protein | HuscFv99 |
|------------------|---------|
| Residues | Domain | Residue(s) | Domain | Interactive bond |
| K107 | Domain I | T58 | VH-CDR2 | H-bond |
| H124 | Domain I | K60 | VH-FR3 | H-bond |
| G125 | Domain I | K60 | VH-FR3 | H-bond |
| R170 | Domain I | D73 | VH-FR3 | Salt bridge |
| D171 | Domain I | R19 | VH-FR1 | Salt bridge |
| E172 | Domain I | R19 | VH-FR1 | Salt bridge |

Continued
to contain several proline-rich motifs, either class-I (+XφPXφP) or class-II (φPXφPX)48. The class–II motifs interact with cellular Src-homology 3 (SH3) adapter proteins and modulate several cellular activities through the respective SH3 downstream signaling pathways including mitogenicity, apoptosis, stress response, protein subcellular localization and cytoskeletal organization49–52. Although the important role of the highly conserved class-I proline rich-motif at residues 26–32 of the NS5A has not yet been elucidated, it is plausible that presumptive binding of the R9-HuscFv5 to K26 and L27 of this motif should have some impact on the unknown activity of the NS5A which should be incompatible with the HCV infectious cycle. The S229 and S232 of the LCS-I are the main hyperphosphorylation sites of the NS5A. Hyperphosphorylated NS5A (p58) has a suggestive role in HCV replication regulation53. Binding of the R9-HuscFv5 to these sites may perturb the p58 activity. Moreover, N-terminal residues 1–148 of the NS5A confers innate immune evasion for the HCV by interacting with 2′,5′-oligoadenylate synthetase (2′,5′-OAS), an important anti-viral protein54. All VH-CDRs and VL-CDR3 of the HuscFv5 were predicted to cooperatively formed contact interface with several NS5A N-terminal residues which should interfere with the NS5A-2′,5′-OAS interaction and consequently restored the host innate immunity. This speculation is fully supported by the finding that expressions of IRF3, IFNB1 as well as IL-28B were regained and even enhanced in the R9-HuscFv5-treated HCV infected cells, compared to the untreated infected Huh7 and the uninfected (normal) cells.

NS5A domain-I binds RNA for HCV replication55. Residues 105–162 of this domain interact with HCV NS5B polymerase and regulate the viral replication56,57. Residues 163–167 of NS5A bound to NS4B for RC formation while residues 1–83 bind to La (LARP3) which is a multifunctional cellular phosphoprotein that involves in several cellular metabolisms and viral RNA activities, such as RNA binding and chaperoning, dsRNA unwinding (helicase activity), mRNA stabilization, RNA polymerase transcripts and cellular microRNA processing, and binding to IRES to mediate HCV translation54,58–62. Residues 163–167 of NS5A bound to NS4B for RC formation, whereas residues 1–83 bind to La (LARP3) which is a multifunctional cellular phosphoprotein that involves in several cellular metabolisms and viral RNA activities, such as RNA binding and chaperoning, dsRNA unwinding (helicase activity), mRNA stabilization, RNA polymerase transcripts and cellular microRNA processing, and binding to IRES to mediate HCV translation54,58–62. Residues 1–110 bound to p85 of cellular phosphoinositide 3-kinase causing up-regulation of the PI3K/Akt cellular survival pathway, possibly for HCV persistence and pathogenesis58–60. Moreover, NS5A residues 123–131 and 155–172 contain Bcl-2 homology (BH) domains 3 and 1, respectively, which protect cells against apoptosis and thus in favor of the HCV replication and pathogenesis60. The HuscFvs, HuscFv16, HuscFv19 and HuscFv99 were predicted to form contact interface with T108, E120, D136, P165, K166, F169, R170, D171 and E172 (Fig. 9B); K107, H124, Y127, Y129, and E191 of domain-I and R220 and E226 of LCS-I (Fig. 9C); H124, G125, Y127, Y129, S186, Q187, and E172 of domain-I, N248 and T249 of LCS-1, and Y250 of domain-II (Fig. 9E), respectively. The interactions should not merely interfere with the NS5A binding to the 2′,5′-OAS and thus rescued the host response as mentioned earlier, but should also perturb the viral replication and other NS5A bioactivities of the NS5A N-terminal regions.

Epitope mapping of the R9-HuscFvs to NS5A. In order to verify the computerized intermolecular docking results which indicated that the R9-HuscFvs bound mainly to the NS5A domain-I, Western blotting were performed using the recombinant GST-tagged D1, D2, and D3 as the antigens. The results shown in Fig. 10 verified the computerized results that all R9-HuscFvs gave positive binding to the NS5A D1 and did not react to the D2 and D3 proteins or the GST tag.

Table 1. Presumptive residues and regions of HCV NS5A bound by the HuscFvs as determined by computerized simulation. LCS-1, low complexity sequence between domains I and II of NS5A.

| HCV NS5A protein | HuscFv5 |
|------------------|--------|
| Residue | Domain | Residue(s) | Domain | Interactive bond |
| Q187 | Domain I | NH4/S85 | VH-CDR3 | H-bond |
| L218 | LCS-I | R57 | VH-CDR2 | H-bond |
| G221 | LCS-I | R57 | VH-CDR2 | H-bond |
| S222 | LCS-I | R57 | VH-CDR2 | H-bond |
| Y250 | Domain II | D62 | VH-FR3 | H-bond |

Concluding remarks. Human monoclonal single chain-transbodies (nonaarginine-linked HuscFvs) to NS5A which is an enigmatic and multifunctional protein in the HCV replication cycle and pathogenesis were produced. The cell penetrating small antibodies inhibited the HCV replication and readily rescued the host innate immune response genes from the viral suppression. Computerized simulation and epitope mapping by immunonosass demonstrated that the effective transbodies interacted mainly with the NS5A domain-I pivotal for HCV replication complex formation, RNA binding, and interaction with several host proteins for viral immune evasion and cellular physiology regulation. Although their molecular mechanisms leading to the observed outcomes await detail laboratory investigations, the cell penetrable HuscFvs have high potential for developing and testing further as a safe, direct acting (possibly interferon free-) anti-HCV agent. To our knowledge, this is the first report on human monoclonal transbodies that interfere with the HCV NS5A activities leading to effective HCV replication inhibition and host immunity restoration.
Figure 9. Computerized interaction of modeled-NS5A and HuscFvs and residues that were predicted to form contact interface between them. Left side of Panels A-E shows interactions of NS5A (beige) and respective HuscFvs (green). Right side of Panels A-E shows contact residues between NS5A and HuscFv5, HuscFv9, HuscFv16, HuscFv19 and HuscFv99, respectively. The NS5A amino acids are colored according to CINEMA color scheme: polar negative D and E are red; polar positive H, K, and R are blue; polar neutral S, T, N, and Q are green; non-polar aromatic F and Y are purple/magenta; non-polar aliphatic A, V, L, I, and M are white (grey in this study as the background is white); and P and G are brown. The π-π interaction is shown as dotted green line; H bond/salt-bridge is shown as dotted yellow line.
Preparation of polyclonal antibody (PAb) to HCV core protein and NS5A. Animal experiments were carried out following Guideline of the National Research Council of Thailand and received approval from the Animal Care and Use Committee of Siriraj Hospital, Mahidol University, Bangkok (SI-ACUP 016/2557). Two groups of three ICR mice were injected individually and intraperitoneally with either 10 μg of recombinant core protein or NS5A mixed with alum adjuvant (1:3 v/v). Three booster doses were given to the primed animals at 14 day intervals using the same dose of the respective immunogens and the same route. One week after last booster, mice were bled and immune sera of individual groups were collected and pooled separately. The
effective concentration 50 (EC\textsubscript{50}) of the anti-core and anti-NS5A immune serum pools were determined by indirect ELISA using 1 μg of the homologous antigens to coat individual wells of the ELISA plate. The immune serum pools were kept in small aliquots at −20 °C until use.

**Production of human monoclonal scFvs (HuscFvs) that bound to NS5A.** The rNS5A was used as antigen in phage biopanning for selecting phages that bound to the protein from a human scFv-phage display library\textsuperscript{67}. The panning was performed as described previously\textsuperscript{43}. The NS5A-bound phage clones were used to transfect the F+ non-suppressor HB2151 E. coli and the phage-transformed bacteria were screened for HuscFv coding sequences (\textit{huscfvs}) by PCR using the pCANTAB-5E phagemid specific primers\textsuperscript{67}. The \textit{huscfv}-positive bacterial colonies were grown under IPTG-induction condition and their lysates were tested for the presence of E-tagged-HuscFvs by Western blotting using rabbit anti-E-tag (Abcam, UK) as the HuscFv tracing reagent. HuscFvs in homogenates of the positive \textit{E. coli} clones were standardized spectrometrically based on the band intensity on the Western blot membrane before testing for binding to the panning antigen by indirect ELISA using one μg of rNS5A to coat each ELISA well. BSA and lysate of original HB2151 \textit{E. coli} clone (HB) were included in the ELISA as control antigen and background binding control, respectively. Nucleotide sequences of huscfv coding for NS5A-bound HuscFvs were determined and deduced. Complementarity determining regions (CDRs) and canonical framework regions (FRs) of individual sequences were worked out using the International Immunogenetics Information System (www.imgt.org).

**Preparation of cell penetrable HuscFvs (transbodies).** Gene sequences coding for NS5A-bound HuscFvs were linked to a sequence coding for nonaarginine (R9). The PCR amplified huscfv were cut with NotI and SfiI restriction enzymes and ligated to pLATE52 vector via the similarly cut sites. The recombinant plasmids were introduced into JM109 \textit{E. coli} (K12) for improving yield and quality of the DNAs before transfecting into Rosetta\textsuperscript{TM} (DE3) \textit{E. coli}. For large scale production of R9-HuscFvs, individual Rosetta \textit{E. coli} clones carrying R9-huscfv-plasmids were grown under 1 mM IPTG induction in 250 ml of 2× YT broth containing 100 μg/ml ampicillin and 34 μg/ml chloramphenicol at 30 °C with shaking (250 rpm) for 6 h. The bacterial IB containing the R9-HuscFvs were purified from the respective bacterial IBs as described above for preparing the recombinant NS5A D1. The R9-HuscFvs were retested for binding to the NS5A protein by Western blot analysis and indirect ELISA.

**In vitro transcription and preparation of HCV infected cells.** HCV cRNA was prepared from \textit{in vitro} transcription of the pJFH-1 as described previously\textsuperscript{68}. Briefly, the pJFH-1 was digested by \textit{I} restriction enzymes and ligated to pLATE52 vector. The linearized plasmid was transfected into Rosetta\textsuperscript{TM} (DE3) \textit{E. coli}. The \textit{I} restricted cRNA was used as the template for the \textit{in vitro} transcription of the plasmid. The R9-HuscFvs were incubated with the cRNA template at 37 °C until use.

**Confocal microscopy for determining intracellular localization of the R9-HuscFvs.** For testing intracellular localization and target binding ability of the R9-HuscFvs, HCV infected cells maintained in complete DMEM on cover slips (1×10\textsuperscript{5} cells/well) in wells of a 24-well tissue culture plate were added with 20 μg of R9-HuscFvs from individual \textit{E. coli} clones in triplicate and incubated for 3 h. After discarding the culture fluids and rinsing the cells with sterile PBS, the cells were fixed and permeated with ice-cold methanol, then washed with sterile PBS, blocked with 1% BSA in PBS, and washed again. Rabbit anti-E tag (Abcam) (300 μl of 1:3,000 dilution) and mouse anti-NS5A immune serum pool (300 μl of 1:300 dilution) were added to the permeated cells and incubated for 1 h. Goat-anti-rabbit immunoglobulin-AlexaFlour\textsuperscript{®}-594 (Life Technologies, USA) (300 μl of 1:300 dilution) and donkey anti-mouse immunoglobulin-AlexaFlour\textsuperscript{®}-488 (Abcam) (300 μl of 1:300 dilution) were used for locating the R9-HuscFvs and NS5A, respectively. DAPI was used for nuclei staining. The stained cells were subjected to laser sectional confocal microscopy.

**Co-immunoprecipitation assay.** Binding of the R9-HuscFvs to native NS5A was demonstrated by co-immunoprecipitation assay. Huh7 cells in complete DMEM were seeded into 6-well plate (1.2×10\textsuperscript{6} cells/well) and incubated at 37 °C in 5% CO\textsubscript{2} incubator overnight. After washing, the cells were added with HCVcc in complete DMEM at MOI 5 and incubated further for 3 more days. R9-HuscFv (50 μg) was added to each well and incubated for 3 h. The culture fluids were discarded and the cells were washed three times with PBS. Five hundred μl of lysis buffer (50 mM Tris-HCl, pH 8.0; 150 mM NaCl and 1% Triton X-100) were added to individual wells. The content in each well was transferred to a microcentrifuge tube and centrifuged (10000 × g, 4 °C, 5 min). The supernatant was added with 5 μl of mouse anti-NS5A (diluted 1:100 in lysis buffer) and kept at 25 °C for 1 h. Protein-G beads (GE Healthcare) (50 μl) were added to the preparation and kept rotating at 4 °C overnight. The beads were set by centrifugation, washed with lysis buffer three times and added with 100 μl of sample buffer (0.5 M Tris-HCl, pH 8.8; 1% SDS, 5% glycerol and 1% Bromophenol Blue), boiled for 10 min and subjected to SDS-PAGE and Western blot analysis by probing with rabbit anti-E-tag (to detect the R9-HuscFvs) and mouse anti-NS5A.

**Kinetics of innate immune gene expression of the HCV infected cells.** Huh7 cells in complete DMEM medium were seeded into wells of a 12-well tissue culture plate (2×10\textsuperscript{5} cells/well) and incubated at 37 °C in CO\textsubscript{2} atmosphere overnight. The cells in each well were infected with HCVcc at MOI 1.0 and incubated. Infected cells from triplicate wells at indicated time points (1, 3, 6, 12, 24, 72 and 120 h post infection) were washed and
RNA was extracted by adding 500μl TriZol reagent. Huh7 cells added with complete DMEM containing 10μg/ml poly(I:C) were used as positive control. Expressions of host innate immune response genes (IFR3, IFNB1 and IL-28B) in the HCV infected and poly(I:C) stimulated cells were determined by qRT-PCR using mRNA levels of the naïve Huh7 cells as baseline.

Inhibition of HCV replication by NS5A-bound transbodies. HCV infected cells in plain DMEM were seeded into wells of a 12-well tissue culture plate (2 x 10⁵ cells/well) and incubated at 37°C in CO₂ atmosphere for 6 h. After discarding the culture fluids, complete DMEM containing 30μg of individual R9-HuscFvs were added appropriately to the cells. Pegylated-IFNα-2a (100 IU) + RBV (50 nM) and 0.175μM telaprevir (VX-950; Selleckem, Houston, TX, USA) served as positive HCV replication inhibition controls. Negative inhibition control was HCV infected cells in medium alone. The treated infected cells were incubated for 5 days. Total RNAs were isolated from culture fluids and cells of individual wells by using TRIzol® reagent (Ambion). The RNAs were used for qRT-PCR as described previously. Briefly, PCR reaction mixture (12.5 μl) which contained 6.25 μl 2 x Brilliant II SYBR Green QRT-PCR master mix, 0.5 μl each of the 5' UTR primers, 0.5 μl RT/RNS block enzyme, 4.75 μl RNA template or 200~900 ng of standard pJFH-1 RNA and sterile DEPC treated-distilled water was prepared. The amplification was carried out using Mx3000P QPCR System (Agilent Technologies). A dissociation curve was analyzed as follows: thermal profile of 95°C for 1 min, ramped down to 55°C for 45 s at a speed of 0.5°C/s, and ramped up to 95°C. Then Log₁₀ RNA copies/ml of each sample was extrapolated from the standard curve which was built from cycle threshold (Ct) of ten-fold serially diluted pJFH-1 (full-length cDNA HCV genotype 2a) which were cal. 2.77 x 10⁷ to 0.02 DNA copies.

HCV foci assay. Numbers of HCV foci of the HCV infected cells treated with NS5A-bound R9-HuscFvs and controls were determined. Treated cells in each well were incubated with 100μl of 1:200 mouse PAb to HCV core protein [effective concentration-50 (EC₅₀) of the anti-HCV core immune serum pool was 1:5,000]. After washing, alkaline phosphatase (AP) conjugated-goat anti-mouse isotype (500μl of 1:3,000 dilution) and 500μl of AP chromogenic substrate (KPL) were used to reveal the foci. HCV infected cells in medium alone and uninfected (normal) cells were included in the experiments. Enumeration of the foci was performed using an inverted fluorescence microscope (NIS-Element D version 4.10.0.8310 W/camera, Ti-S Intensilight Rl NIS-D, Nikon, Japan) at 40 x magnification.

Response of HCV infected cells to treatment with NS5A-bound R9-HuscFvs. RNAs isolated from the HCV infected cells after treating with NS5A-bound R9-HuscFvs and controls (300 ng each) were used as templates for quantification of innate immune response genes including IFR3, IFNB1, and IL-28B by qRT-PCR. GAPDH RNA was used for normalization. The qRT-PCR was performed as for quantification of the HCV 5' UTR by qRT-PCR described above using primers specific to the innate genes. Ct of individual genes were compared with the house keeping gene (ΔΔCt) and subtracted by background ΔCt of normal cells. Data (ΔΔCt) are expressed as fold change of individual genes in the HCV infected cells treated with the R9-HuscFvs and controls in comparison to the normal cells.

Computerized simulation for determining presumptive NS5A regions and residues bound by the HuscFvs. Three dimensional model of the HCV NS5A molecule was acquired from template-based protein structure modeling using RaptorX webserver. The sequence of the pJFH-1 NS5A showed the highest homology with PDB 3FQM. Validation of the acquired model was performed according to the criteria of VADAR version 1.8. The HuscFv sequences were submitted to I-TASSER service for modeling and the models were subsequently refined by ModRefiner and Fragment Guided Molecular Dynamics (FG-MD) simulation for making them become closer to their native state. The modeled NS5A and the HuscFvs were subjected to ClusPro2.0 server for determining their contact interface. The intermolecular docking which showed the largest cluster of interactive residues with the lowest local energy was selected. Pymol software (The PyMOL Molecular Graphics System, Version 1.3r1 edu, Schrodinger, LLC, NY, USA) was used for building the molecular interactive protein structure models.

Western blot analysis for determining the NS5A domain bound by the R9-HuscFvs. Recombinant D1, D2, and D3 proteins with GST-tag were subjected to SDS-PAGE and the separated components were electroblotted onto nitrocellulose membranes (NC). GST was included as antigen control. After blocking the NC empty sites with 5% skim milk, the membranes were air-dried and cut vertically into strips. Individual strips were incubated appropriately with the E-tagged-R9-HuscFvs. After incubating and washing, all NC strips were probed with rabbit monoclonal anti-E tag antibody (Abcam). Horseradish peroxidase (HRP)-conjugated-goat anti-rabbit isotype (Southern Biotech, Birmingham, USA) and HRP substrate (Luminata® Crescendo Western HRP Substrate; Merck Millipore, MA, USA) were used for revealing the antigen-antibody reactive bands on the membrane. Negative controls (N) were respective antigen-blotted strips probed with buffer while positive controls were antigen-blotted strips probed with rabbit anti-GST.

Statistical analysis. Unpaired Student t-test was used for comparison of the results of the tests and the controls. P-value < 0.05 was taken as statistically significant.
References

1. World Health Organization. Guideline for the Screening, Care and Treatment of Persons with Chronic Hepatitis C Infection; April 2016. (accessed on April 2017).
2. Zein, N. N. Clinical significance of hepatitis C virus genotypes. Clin. Microbiol. Rev. 13(2), 223–235 (2000).
3. Zoulim, F., Chevallier, M., Maynard, M. & Trepo, C. Clinical consequences of hepatitis C virus infection. Rev. Med. Virol. 13, 57–68 (2003).
4. Foster, G. & Mathurin, P. Hepatitis C virus therapy to date. Antiviral. Ther. 13, 1–8 (2008).
5. Wang, M. T. & Chen, S. S.-L. Emerging roles of interferon-stimulated genes in the innate immune response to hepatitis C virus infection. Cell. Mol. Immunol. 13, 11–35 (2016).
6. Manns, M. P., Wedemeyer, H. & Cornberg, M. Treating viral hepatitis C: efficacy, side effects, and complications. Gut 55, 1350–1359 (2006).
7. Pang, P. S., Planet, P. J., Jeffrey, S. & Glenn, J. S. The evolution of the major hepatitis C genotypes correlates with clinical response to interferon therapy. PLoS ONE 4(8), e6579 (2009).
8. Zhang, X. Direct anti-HCV agents. Acta Pharmacuet. Sinica B. 6, 26–31 (2016).
9. Wu, S., Kanda, T., Nakamoto, S., Imaseki, F. & Yokosuka, O. Hepatitis C virus protease inhibitor-resistance mutations: our experience and review. World J. Gastroenterol. 19(47), 8940–8948 (2013).
10. Kiser, J. J. & Flexner, C. Direct acting antiviral agents for hepatitis C virus infection. Annu. Rev. Pharmacol. Toxicol. 53, 427–449 (2013).
11. Cooper, C. et al. Direct-acting antiviral therapies for hepatitis C genotype 1 infection: a multiple treatment comparison meta-analysis. Q. J. Med. 106, 153–163 (2013).
12. Lin, M. V. & Chung, R. Recent FDA approval of sofosbuvir and simeprevir. Implications for current HCV treatment. Clin. Liver Dis. 3, 65–68 (2014).
13. Hilgenfeld, E. G., Schlachterman, A. & Firpi, R. J. Hepatitis C: treatment of difficult to treat patients. Indian J. Med. Res. 133, 71–77 (2010).
14. Egger, D. et al. Expression of hepatitis C virus proteins induces distinct membrane alterations including a candidate viral replication complex. J. Virol. 76, 5974–5984 (2002).
15. Lindenbach, B. D. & Rice, C. M. Unraveling hepatitis C virus replication from genome to function. Nature 436, 933–938 (2005).
16. MacDonald, A. & Harris, M. Hepatitis C virus NS5A: tales of a promiscuous protein. J. Gen. Virol. 85, 2485–2502 (2004).
17. He, Y., Staschke, K. A. & Tan, S. L. HCV NS5A: a multifunctional regulator of cellular pathways and virus replication. In: Hepatitis C Viruses: Genomes and Molecular Biology. Tan, S. L., ed. Horizon Bioscience, Norfolk (UK) (2006).
18. Appel, N. et al. Essential role of domain III of nonstructural protein 5A for hepatitis C virus infectious particles assembly. PLoS Pathog. 4, e1000035 (2008).
19. Friddell, R. A. et al. Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in humans: in vitro and in vivo correlations. Hepatology 54(6), 1924–1935 (2011).
20. Ghosh, A. K., Steele, R., Meyer, K., Ray, R. & Ray, R. B. Hepatitis C virus NS5A protein modulates cell cycle regulatory genes and promotes cell growth. J. Gen. Virol. 80, 1179–1183 (1999).
21. Sharma, S. D. Hepatitis C virus: molecular biology & current therapeutic options. Indian J. Med. Res. 131, 17–34 (2010).
22. Higgins, M. R., Lerat, H. & Pawlotsky, J. M. Hepatitis C virus-induced activation of beta-catenin promotes c-Myc expression and a cascade of pro-carcinogenic events. Oncogene 32, 4683–4693 (2013).
23. Pawlotsky, J. M. NS5A inhibitors in the treatment of hepatitis C. J. Hepatol. 59, 375–382 (2013).
24. Huang, L. et al. Hepatitis C virus nonstructural protein 5A (NS5A) is an RNA-binding protein. J. Biol. Chem. 280, 36417–36428 (2005).
25. Kaneko, T. et al. Production of two phosphoproteins from the NS5A region of the hepatitis C viral genome. Biochem. Biophys. Res. Com. 205, 320–326 (1994).
26. Kim, J., Lee, D. & Choe, J. Hepatitis C virus NS5A protein is phosphorylated by casein kinase II. Biochem. Biophys. Res. Com. 257, 777–781 (1999).
27. Quintavalle, M., Sambucini, S., Di Pietro, C., De Francesco, R. & Neddermann, F. The alpha isoform of protein kinase CCKI is responsible for hepatitis C virus NS5A hyperphosphorylation. J. Virol. 80, 11305–11312 (2006).
28. Asabe, S. I. et al. The N-terminal region of hepatitis C virus-encoded NS5A is important for NS5A-dependent phosphorylation. J. Virol. 71(1), 790–796 (1997).
29. Nedderman, P., Clement, A. & De Franceso, R. Hyperphosphorylation of the hepatitis C virus NS5A protein requires an active NS3 protease, NS4B, and NS5A encoded on the same polyprotein. J. Virol. 73(12), 9984–9991 (1999).
30. Elazar, M. et al. Amphilipic helix-dependent localization of NS4A mediates hepatitis C virus RNA replication. J. Virol. 77, 6055–6061 (2003).
31. Penin, F. et al. Structure and function of the membrane anchor domain of hepatitis C virus nonstructural protein 5A. J. Biol. Chem. 278, 40835–40843 (2004).
32. Tellinghusen, T. L., Marcotrigiano, J. & Rice, C. M. Structure of the zinc-binding domain of an essential component of the hepatitis C virus replicase. Nature 435, 374–379 (2005).
33. Foster, T. L., Belyaev, T., Stonehouse, N. J., Pearson, A. R. & Harris, M. All three domains of the hepatitis C virus nonstructural NS5A protein contribute to hepatitis B virus infection complex. J. Virol. 84(18), 9267–9277 (2010).
34. Love, R. A., Brodsky, O., Hickey, M. J., Wells, P. A. & Cronin, C. Crystal structure of a novel dimeric form of NS5A domain II from hepatitis C virus. J. Virol. 83, 4395–4403 (2009).
35. Belda, O. & Targett-Adam, P. Small molecule inhibitors of the hepatitis C virus-encoded NS5A protein. Virus Res. 170, 1–14 (2012).
36. Forthal, D. N. Functions of antibodies. Microbiol. Spectr. 2(4), 1–17 (2014).
37. Kristensen, M., Birch, D. & Nelsen, H. M. Applications and challenges for use of cell-penetrating peptides as delivery vectors for peptide and protein cargos. Int. J. Mol. Sci. 17, 185 (2016).
38. Liu, J. et al. Cell-penetrating peptide-mediated delivery of TALEN proteins via bioconjugation for genome engineering. PLOS ONE 9, e85755 (2014).
39. Hittavuohikul, S. et al. Human transbodies to HCV NS3/4A protease inhibit viral replication and restore host innate immunity. Front. Immunol. 7, 318 (2016).
40. Wakita, T. et al. Production of infectious hepatitis C virus in tissue culture from a clone of viral genome. Nat. Med. 11, 791–6 (2005).
41. Zhong, J. et al. Robust hepatitis C virus infection in vitro. Proc. Natl. Acad. Sci. USA 102, 9294–9299 (2005).
42. Keril, J., Blight, K. J. & Norgard, E. A. HCV replicon systems. In Hepatitis C Viruses: Genomes and Molecular Biology. Tan, S. L., ed. Horizon Bioscience; Norfolk, UK (2006).
43. Glab-ampai, K. et al. Inhibition of HCV replication by humanized-single domain transbodies to NS4B. Biochem. Biophys. Res. Com. 476(4), 654–666 (2016).
44. Li, K. et al. Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the toll-like receptor 3 adapter protein TRIF. Proc. Natl. Acad. Sci. USA 102(8), 2992–2997 (2005).
45. Li, X. D., Sun, L., Seth, R. B., Pineda, G. & Chen, Z. Hepatitis C virus protease NS3/4A cleaves mitochondrial antiviral signaling protein of the mitochondria to evade innate immunity. Proc. Natl. Acad. Sci. USA 102(49), 17717–17722 (2005).
66. Chung, Y. L., Sheu, M. L. & Yen, S. H. Hepatitis C virus NS5A as a potential viral Bcl-2 homologue interacts with Bax and inhibits apoptosis in hepatocellular carcinoma. J. Virol. 78, 2738–2748 (2004).

67. Kulkeaw, K.

68. Thueng-in, K.

69. Ma, J.

70. Tan, S. L.

71. I-Tasser Online, Protein Structure & Function Prediction—Google Search. Available online: http://zhanglab.ccmb.med.umich.edu/I-TASSER/ (accessed in July 2016).

72. FG-MD: High-Resolution Proteins Structure Refinement by Fragment-Guided MD Simulation. Available online: http://zhanglab.ccmb.med.umich.edu/FG-MD/ (accessed in Aug 2016).

73. FG-MD: High-Resolution Proteins Structure Refinement by Fragment-Guided MD Simulation. Available online: http://zhanglab.ccmb.med.umich.edu/ModRefiner/ (accessed in Aug 2016).

74. Kozakov, D.

75. How good is automated protein docking? Proteins 81, 2159–2166 (2013).

Acknowledgements

The work was co-supported by NSTDA Chair Professor grant (P-1450624) funded by the Crown Property Bureau of Thailand and the Thailand Research Fund (TRF) (DPG5380001). K.G.A. received Royal Golden Jubilee Ph. D. Program scholarship, TRF. M.C.N. and J.T.N. are the TRF-MRG scholars. N.S.R. is the TRF-RSA scholar. The authors thank Dr. Takaji Wakita, Department of Microbiology, Tokyo Metropolitan Institute for Neuroscience, Tokyo, Japan and Dr. Ralf Batenschlaeger, Department of Molecular Virology, University of Heidelberg, Germany, for providing the pJFH-1. Huh7 cells were from Dr. Thawornchai Limjindaporn, Faculty of Medicine Siriraj Hospital, Mahidol University.

Author Contributions

W.C.C. conceived the project, designed experiments, supervised the research team, interpreted the experimental data, and wrote the manuscript. K.G.A. did most experiments and prepared figures. M.C.N. helped K.G.A. side-by-side and cloned NS5A domains. T.J.D. produced rNS5A and did the phage biopanning. A.A.M. performed the computerized intermolecular docking. P.S.R., J.T.S., K.T.I., N.S.R., and P.T.T. helped W.C.C. to supervise K.G.A.

Additional Information

Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-017-14886-9.

Competing Interests: The authors declare that they have no competing interests.

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
